Licensing analysis: big deals bolster biotech
PD-(L)1 x VEGF bispecifics prove a big draw.
ASCO 2025 – BioNTech shows promise in mesothelioma
BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.
Pfizer bets big on a bispecific
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
DualityBio tries to float again
The group expects to raise nearly $170m.
FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
ELCC 2025 – BioNTech impresses in small-cell lung
In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.
